The COLIC Study: Colonization of the Infant Gut With B. Infantis EVC001 to Reduce Symptoms of Colic

Evolve BioSystems

Status

Terminated

Conditions

Infantile Colic

Treatments

Dietary Supplement: B. infantis EVC001 or Lactose Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT05129384

EV-9101

Details and patient eligibility

About

To investigate whether B. infantis EVC001 colonization in the infant gut can reduce symptoms of colic

Full description

There is evidence to support that B. infantis EVC001 supplementation may ameliorate symptoms associated with colic by establishing and maintaining the necessary gut microbial composition to promote proper barrier and immune function in infants. The primary objective of this study is to assess the effect of the probiotic, B. infantis EVC001, on reducing the duration of crying/fussing symptoms of breastfed infants diagnosed with infantile colic from Baseline to Day 14.

Enrollment

1 patient

Sex

All

Ages

14 to 42 days old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Infants with a diagnosis of infantile colic per Rome IV criteria and reported to cry/fuss for ≥ 3 hours/day, within a 24-hour period as determined by the 24-hour cry/fuss eDiary AND 24 hours of LENA vocalizations
Infants with a gestational period of ≥ 37 to 42 weeks
Infants between 14 and ≤ 42 days of life at the completion of screening/baseline tasks
Infants exclusively breastfed for at least 7 days immediately prior to enrollment and with mother's intent to continue feeding breast milk exclusively for the duration of the study
Mothers willing to use their own electronic device(s) to download and utilize all required study software (decentralized trial platform on a mobile device and the LENA device software on a Windows 10 or higher laptop or desktop that has at least 10 GB of free space and fast, reliable internet)
Mother is fluent in English

Exclusion criteria

Infants born in multiple birth (i.e., twins, triplets, etc.)
Infants born with medical complications (i.e., neurological, cerebral palsy, confirmed food allergies)
Infants with current evidence of failure to thrive, fever, or illness
Infants with any GI tract abnormalities
Antibiotic, infant formula, solid food or iron supplement intake within 7 days prior to enrollment or mother's intent to feed non-study probiotics, prebiotics, infant formula, solid food or iron supplements to their infant at any time during the study
Infants who have consumed any probiotics since birth
Unwillingness to discontinue/avoid products used to treat IC (i.e., Simethicone, gripe water, colic drops, etc.) during the study. Note: consumption of IC products prior to the baseline period is NOT exclusionary
Maternal use of probiotics containing B. infantis during pregnancy, after the baby's birth and/or intent to use probiotics containing B. infantis at any time throughout the study
Maternal smoking or smoking within the home by any household member currently or during pregnancy
Mother following exclusionary diet due to her infant's colic (i.e., dairy elimination diet)
Any infant the Investigator deems to be ineligible for participation